Advanced Cell Diagnostics (ACD) is a Hayward, California–based leader in in situ nucleic acid detection for life science research and clinical diagnostics. Its core product is the proprietary RNAscope® technology for detecting RNA in situ. The company plans to accelerate entry into the research and clinical diagnostics markets and to launch new technology platforms built on RNAscope. Proceeds from the financing will be used to fund those market-entry and product-launch initiatives. ACD completed a $22M Series C equity financing to support this growth. The company is led by Founder, President and CEO Dr. Yuling Luo. Advanced Cell Diagnostics (ACD) is a Hayward, California-based life science research and clinical diagnostics company focused on cell- and tissue-based diagnostic tests for personalized medicine. Its products and services are built on the proprietary RNAscope® technology, a multiplex fluorescent and chromogenic in situ hybridization platform capable of detecting and quantifying RNA biomarkers in situ at single-molecule sensitivity. ACD partners with pharmaceutical and biotechnology companies to validate biomarkers for targeted therapeutic development in cancer and other diseases. The company raised $12M in Series B financing; backers include New Leaf Venture Partners and Morningside Ventures. ACD intends to use the capital to expand commercial efforts for RNAscope-based products and services into the life science research market and to accelerate RNAscope's entry into the clinical diagnostics market. The company is led by Dr. Yuling Luo, Founder, President and CEO. Advanced Cell Diagnostics is a Hayward, California–based company that develops cell- and tissue-based diagnostic tests. Its products and services are built on RNAscope, a proprietary multiplex fluorescent and chromogenic in situ hybridization platform capable of detecting and quantifying RNA biomarkers in situ at single-molecule sensitivity. The company completed the second closing of its Series A equity financing from Morningside Ventures, bringing the total raised in this round to $5.4M. The funds will allow the company to further develop its cell- and tissue-based diagnostic tests. Founder, President and CEO Dr. Yuling Luo said the company will offer development expertise in RNA analysis for biomarker validation and companion diagnostic development in partnership with pharmaceutical and biotechnology companies.

Total raised

$39M

Funding rounds

3

Latest round

Series C

Latest activity

Jun 2015